Early Investigator Awards

Lynn Sage Scholar research grants that support early-career researchers launching bold new ideas in breast cancer research.

Focus Areas:

• Breast cancer detection and treatment improvements
• Triple negative breast cancer (TNBC)
• Tumor extracellular vesicles and immune regulation
• Artificial intelligence applications in breast cancer
• Immunotherapy and personalized medicine
• Breast cancer biomarkers and diagnostics

Geographic Scope: Chicago-area based researchers, though investments drive impact globally

Eligibility: Early-career researchers at academic institutions

Current & Past Investigators Include:

• Dr. Lamiaa El-Shennawy, Northwestern University Feinberg School of Medicine
• Dr. Frederick Howard, University of Chicago
• Jeffrey Schneider, PhD, Rush University Medical Center
• Dr. Nurmaa K. Dashzeveg (2024-25)
• Dr. Nan Chen (2024-25)
• Dr. Peiwen Chen (2022-23)
• Dr. Arjun Raman (2022-23)
• Dr. Lu Wang (2022-23)
• Dr. Zhe Ji (2020-22)
• Elizabeth Hibler, PhD (2020-22)

Contact:

• Phone: 312.252.2502
• Email: info@lynnsage.org
• Address: 3023 N. Clark Street Suite 139, Chicago, IL 60657

Background: Lynn Sage was an early investor in the study of Tamoxifen, which is now the standard of care treatment for hormone-receptor-positive breast cancer. 94% of funds raised go to research & education.